Five years after sharing her journey, Amoye Henry sees progress for Black women founders in Canada.Amoye Henry is an investor, ecosystem catalyst and global consultant backing visionaries and challenging the status quo. She is the co-founder of Pitch Better, a startup that trains entrepreneurs to build and scale sustainable small businesses.In 2020, I wrote an article for BetaKit titled “The horrifying truth of being a Black woman founder in Canada.” It revealed a painful truth: across thousands of Canadia ...

All three are buys, but for different reasons.Fears of a recession did not materialize this year. However, it's always worth it for investors to buy shares of companies that can perform well during economic downturns. Solid dividend stocks that routinely increase their payouts are especially attractive in that regard, since they tend to have businesses equipped to withstand challenging times.Let's discuss three stocks to buy to prepare your portfolio for any recession that may lay ahead: Microsoft (MSFT 0.5 ...

Market Performance - Major U.S. indexes ended the Christmas-shortened week higher, with the S&P 500 and Dow reaching new record highs, gaining 0.75% and 0.72% respectively, while the Nasdaq Composite increased by 0.70% [1] - The U.S. GDP growth rate for Q3 2025 was 4.3%, exceeding expectations and marking the fastest growth since Q3 2023 [2] - Despite a decline in consumer confidence, investor optimism is driven by strong corporate earnings outlook and AI enthusiasm [2] Stock Performance - Castle Biosciences, Inc. (CSTL) shares increased by 77.9% since being upgraded to a Zacks Rank 1 (Strong Buy) on October 20, significantly outperforming the S&P 500's 3.8% increase [3][6] - F.N.B. Corporation (FNB) shares rose by 13.4% after its upgrade to Zacks Rank 2 (Buy) on October 21, compared to the S&P 500's 2.8% increase [4] - Hamilton Insurance Group, Ltd. (HG) and Kinross Gold Corporation (KGC) saw gains of 19.8% and 7.7% respectively since their upgrade to Outperform on October 17 [7] Portfolio Performance - A hypothetical portfolio of Zacks Rank 1 stocks returned +14.3% in 2025, slightly underperforming the S&P 500's +14.9% [11] - The Zacks Model Portfolio has outperformed the S&P 500 index by over 12 percentage points since 1988, with an annualized average return of +23.9% compared to +11.5% for the S&P 500 [13] - The Zacks Earnings Certain Admiral Portfolio (ECAP) returned -1.30% in Q3 2025, underperforming the S&P 500's +8.1% gain [15] Dividend Portfolio Performance - Johnson & Johnson (JNJ) returned 14.3% over the past 12 weeks, while 3M Company (MMM) increased by 5.2% during the same period [18] - The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -0.01% in Q3 2025, compared to the S&P 500's +8.1% gain [19]

December 26, 2025 01:59 PM GMT Biopharma | North America A picture is worth a thousand words Comprehensive US drug market analysis (IQVIA Rx). The latest weekly Total Prescription YoY growth (wk ending 12/19) was +1.1% vs. +1.0% last wk and +0.8% over the past 12 wks. GILD's Yeztugo vs. Descovy vs. Apretude launch comparison chart ( Exhibit 4 ). GILD's Yeztugo (lenacapavir) was approved on 6/18/2025. Latest week total TRx (oral + injectable) were ~780 vs. ~800 previous week, and last week TRx for injectable ...

Core Insights - Johnson & Johnson has successfully completed the acquisition of Halda Therapeutics for $3.05 billion in cash, enhancing its oncology portfolio with innovative therapies for solid tumors, including prostate cancer [1][2] Group 1: Acquisition Details - The acquisition of Halda Therapeutics includes the addition of HLD-0915, a clinical-stage therapy for prostate cancer, which utilizes the proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform [2] - The deal is expected to result in a dilution of approximately $0.20 to Adjusted Earnings Per Share (EPS), split equally between 2025 and 2026, due to non-recurring charges related to Halda employee equity awards and integration costs [3] Group 2: Strategic Goals - The acquisition is part of Johnson & Johnson's commitment to redefining cancer treatment through breakthrough science and transformative medicines, aiming to eliminate cancer [2] - The company plans to leverage the RIPTAC™ platform to advance a promising pipeline of novel product candidates and discover more molecules in oncology and beyond [3]

Core Insights - The pharmaceutical industry is experiencing significant performance divergence among major multinational companies in 2025, with some companies thriving while others face substantial challenges [1][2][3][4]. Financial Performance - Novo Nordisk reported Q3 2025 revenues of 74.976 billion Danish Krone (approximately $11.276 billion), a year-on-year increase of 11%, with total revenues for the first three quarters reaching 229.92 billion Danish Krone (approximately $34.58 billion), up 15% [1]. - Key products such as Ozempic, Rybelsus, and Wegovy contributed significantly to Novo Nordisk's revenue, with Wegovy showing a remarkable growth of 54% [1]. - Merck's pharmaceutical revenue for the first three quarters of 2025 was $43.299 billion, with a 68% decline in revenue from China, dropping to $1.452 billion [2]. - Eli Lilly achieved a remarkable turnaround with Q3 revenues of $17.6 billion, a 54% increase year-on-year, driven by the success of its GLP-1 drug [3]. - Pfizer was the only company in the top 10 to experience a decline in both revenue and profit, with Q3 revenues of $16.654 billion, down 6% year-on-year [4]. Strategic Adjustments - Major pharmaceutical companies are actively seeking solutions to address strategic challenges, including layoffs and business divestitures, with 190 layoffs reported in the first three quarters of 2025 [2][9]. - Companies like Merck and Novo Nordisk are implementing significant cost-cutting measures, with Merck aiming to save $3 billion by 2027 and Novo Nordisk planning to cut approximately 9,000 jobs [2][9]. - The trend of divesting mature assets is becoming common, with companies opting to sell off non-core or underperforming business units to focus on innovation [7][9]. Market Dynamics - The Chinese market is no longer a guaranteed success for multinational pharmaceutical companies, with significant performance disparities emerging [5][12]. - The ongoing "patent cliff" is a critical concern, with many companies facing over 20% of their revenue at risk due to expiring patents [5]. - The competitive landscape is shifting, with local investment firms increasingly acquiring mature products from multinational companies, allowing for more localized management and decision-making [8][9]. Future Outlook - The future of multinational pharmaceutical companies will depend on their ability to innovate rapidly, adapt to local market policies, and manage patent expirations effectively [12][14]. - Companies that can successfully transition to innovation-driven models and integrate into China's biopharmaceutical ecosystem are likely to thrive [12][14]. - The restructuring of global pharmaceutical companies is creating both challenges and opportunities for local firms, as they may benefit from the divestiture of mature products and increased collaboration on early-stage innovations [14].

Core Insights - The article discusses the expertise of Fred Piard, a quantitative analyst with over 30 years in technology, focusing on data-driven systematic investment strategies since 2010 [1]. Group 1: Expertise and Background - Fred Piard has authored three books and runs an investing group called Quantitative Risk & Value, which focuses on quality dividend stocks and innovative tech companies [1]. - He provides various market strategies, including market risk indicators, real estate, bond, and income strategies in closed-end funds [1].

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

【深圳商报讯】(记者刘娥)我国生物医用材料领域取得重大突破。近期，由深圳华诺生物科技有限公司 自主研发的"可吸收止血流体凝胶"获得国家药品监督管理局(NMPA)三类医疗器械注册证，成功打破美 国强生公司在该高端止血耗材领域长达10年的市场垄断。华诺生物科技创始人，大连理工大学教授、博 导王华楠表示，截至目前，该产品已实现近千家医院入院，预计到2026年将实现强生产品30%—40%的 市场替代，未来5年完成全面替代。 这一突破性成果源自王华楠团队17年的持续研发。与传统材料依赖稳定的共价键不同，华诺生物创新 的"自愈合分子技术"基于"动态非共价键"原理，使材料在被破坏后能够快速重组恢复结构和强度。该技 术同时具备了流体的可注射性和固体的支撑能力，在微创手术中，医生可以通过腹腔镜将材料精准注入 体内深处出血点，实现快速止血封闭。 业内专家指出，随着国家加大对高端医疗器械产业的支持力度，未来5—10年将是中国医疗器械耗材企 业集中爆发期。华诺生物的成功案例表明，通过产学研深度融合，中国企业在高端医疗耗材领域完全有 能力突破技术壁垒，实现从跟跑到并跑甚至领跑的跨越。 目前，华诺生物已与多家国际机构开展合作，其自主研发 ...

Core Perspective - The government is shifting its focus towards railway safety, with a modest increase in spending for FY26 [1] Group 1: Government Spending - The outlay for railway safety increased by only 2% in FY26 [1] - Historically, railway capital and revenue spending on safety has accounted for approximately 20% of the total budget [1] Group 2: Recent Incidents - The renewed focus on safety follows a train collision in Bilaspur, Chhattisgarh, which resulted in 11 fatalities and around 20 injuries [1]